Trials / Completed
CompletedNCT05048719
A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 383 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3502970 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 30 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3502970 | Administered orally |
| DRUG | Dulaglutide | Administered subcutaneously |
| DRUG | Placebo | Administered orally |
| DRUG | Placebo | Administered subcutaneously |
Timeline
- Start date
- 2021-09-15
- Primary completion
- 2022-09-30
- Completion
- 2022-09-30
- First posted
- 2021-09-17
- Last updated
- 2023-10-17
- Results posted
- 2023-10-17
Locations
44 sites across 5 countries: United States, Hungary, Poland, Puerto Rico, Slovakia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05048719. Inclusion in this directory is not an endorsement.